Mumbai, Feb. 5 -- Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during thr quarter.
Profit before tax (PBT) jumped 27.94% to Rs 1,184.1 crore in Q3 FY25 compared with Rs 925.5 crore in Q3 FY24.
EBITDA for the quarter was Rs 1387.6 crore, up 26% YoY. EBITDA margin for the quarter stood at 26.3%, which is an improvement of 180 bps on a YoY basis.
Research & Development (R&D) investments for the quarter stood at Rs 503.1 crore in Q3 FY25, which represented 9.5% of revenues. Additionally, organic capital expenditures (Capex) stood at Rs 290.7 crore in Q3 FY25.
In terms of segment revenue, India formulations business grew by 5% YoY to Rs 1,498.2 crore.
Revenue from US Formulation business stood at Rs 2,409.6 crore in Q3...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.